25-hydroxyvitamin D status in patients with alopecia areata

Basit Öğe Kaydı
dc.contributor.authorErpolat, Seval
dc.contributor.authorSarifakioglu, Evren
dc.contributor.authorAyyildiz, Abdullah
dc.date.accessioned2025-10-24T18:10:02Z
dc.date.available2025-10-24T18:10:02Z
dc.date.issued2017
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractIntroduction: Alopecia areata (AA) is a T cell-mediated autoimmune disease that causes inflammation around anagen-phase hair follicles. Insufficient levels of vitamin D have been implicated in a variety of autoimmune diseases. Aim: To investigate the status of serum 25-hydroxyvitamin D (25(OH)D) in patients with AA, serum 25(OH)D concentrations were compared between AA patients and healthy controls and thus determine if a possible association exists between serum 25(OH)D levels and AA. Material and methods: The study comprising 41 patients diagnosed with AA and 32 healthy controls was conducted between October 2010 and March 2011. The serum vitamin D levels of the study group were determined by high performance liquid chromatography. Serum levels of calcium, phosphorus, alkaline phosphatase, and parathyroid hormone were also evaluated. Results: The study was based on 41 patients aged between 20 and 50 (mean: 32.8 +/- 7.5). The control group included 32 healthy persons aged between 20 and 51 (mean: 32.7 +/- 7.5). Serum 25(OH)D levels in patients with AA ranged from 5.0 to 38.6 ng/ml with a mean of 8.1 ng/ml. Serum 25(OH)D levels in healthy controls ranged from 3.6 to 38.5 ng/ml with a mean of 9.8 ng/ml. There was no statistically significant difference in the serum vitamin D level between AA patients and healthy controls (p > 0.05). Conclusions: Deficient serum 25(OH)D levels are present in patients with AA. However, considering the high prevalence of vitamin D deficiency in Turkey, no difference was noted between AA patients and controls.
dc.identifier.doi10.5114/ada.2017.67847
dc.identifier.endpage252
dc.identifier.issn1642-395X
dc.identifier.issue3
dc.identifier.pmid28670255
dc.identifier.scopus2-s2.0-85019991922
dc.identifier.scopusqualityQ2
dc.identifier.startpage248
dc.identifier.urihttps://doi.org/10.5114/ada.2017.67847
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3954
dc.identifier.volume34
dc.identifier.wosWOS:000403386700011
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofPostepy Dermatologii I Alergologii
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectalopecia areata; autoimmunity; vitamin D
dc.title25-hydroxyvitamin D status in patients with alopecia areata
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu